Applications of Oxaliplatin in Industrial Manufacturing

Oxaliplatin is a third-generation platinum-based anticancer active pharmaceutical ingredient (API) with highly specialized applications in the pharmaceutical manufacturing sector. As a leading manufacturer, we supply oxaliplatin to key segments demanding stringent quality control and traceable process integration. Below, we present the primary downstream applications and the specific technical requirements for each field.

1. Injectable Oncology Drug Formulation

Injectable oncology drugs are the largest downstream application for oxaliplatin. Hospital-grade cytotoxic injectables use oxaliplatin as an active compound for colorectal cancer regimens. Pharmaceutical companies source the API in GMP-compliant powder form for fill-finish lines. Manufacturers strictly control the API-to-excipient ratio, solubility, and stability profiles throughout scaled batch production. Regulatory filings reference compendial monographs and dossier data for release specifications and in-use shelf life.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Part II Pharma APIs
• US FDA 21 CFR Parts 210/211
• European Pharmacopoeia (Ph. Eur.), United States Pharmacopeia (USP) monographs for oxaliplatin

Typical usage ratio

• API loading ranges from 5 mg/mL to 10 mg/mL for finished injectable vials, with final adjustment according to clinical protocol and national drug authority approval

Downstream process integration

• API blending with excipients in sterile, validated compounding vessels
• In-line filtration and isocratic dissolution under aseptic conditions
• Terminal sterilization or aseptic fill-finish as required

Final product types

• Ready-to-use injectable vials for cancer therapy
• Lyophilized powder vials for hospital pharmacies
• Pre-filled syringes for clinical oncology use

2. Lyophilized Bulk API Manufacturing

Contract development and manufacturing organizations (CDMOs) and bulk API producers order oxaliplatin for advanced lyophilization processes. The substance undergoes controlled freeze-drying cycles to reach precise particle size and moisture content, ensuring stability through global transportation. Careful monitoring of water content and reconstitution is essential. Process validation matches the regulatory filings and supports global drug master files (DMF).

Industry compliance standards

• ICH Q8 Pharmaceutical Development
• ICH Q6A Specifications: Test Procedures and Acceptance Criteria
• Chinese Pharmacopoeia (ChP) for moisture content and impurity limits

Typical usage ratio

• Freeze-dried oxaliplatin typically produced at a concentration of 99.8%+ purity with 2–5% allowed reconstitution excipients, depending on downstream stability requirements

Downstream process integration

• Loading into lyophilizer trays following micronization
• Ramp-down freezing, primary and secondary drying to target residual moisture
• Sampling and release according to stability-indicating methods

Final product types

• Bulk lyophilized API supplied in sealed vials
• Master lots for licensed oncology injectable production
• Precursor material for combination therapies and further formulation

3. Oncology Combination Drug Production

Combination regimens such as FOLFOX integrate oxaliplatin with fluorouracil and leucovorin during secondary formulation. Drug product manufacturers meter precise quantities of each API using validated protocols to achieve defined fixed-dose combinations. These lines require cross-contamination control and multi-component blending under monitored environments. QA verifies blend uniformity and API content in final dosage forms for clinical use.

Industry compliance standards

• EU EMA Guideline on Fixed Combination Medicinal Products
• US FDA Guidance for Industry: Codevelopment of Two or More New Investigational Drugs for Use in Combination
• WHO Prequalification Programme

Typical usage ratio

• Common oxaliplatin doses: 85 mg/m² in premixed infusion bags, with mass ratios tailored according to protocol for other actives

Downstream process integration

• Weighing and dispensing under class 100 cleanrooms
• Blending with additional cytotoxic APIs
• Co-packaging for simultaneous administration in clinical settings

Final product types

• Co-formulated infusion solutions
• Combined lyophilized powder vials
• Customized hospital packs for oncology protocols

4. Reference Standard and Analytical Laboratory Supply

Certified reference standards based on oxaliplatin ensure quality control and regulatory compliance for medicinal chemistry laboratories. Analytical labs rely on precisely formulated and verified reference materials to validate chemical identity, purity, and content of drug substances produced in bulk. Strict chain of custody and documentary traceability are maintained from source to laboratory delivery.

Industry compliance standards

• ISO 17025 General requirements for the competence of testing and calibration laboratories
• Pharmacopoeial Reference Standards (BP/USP/EP/JP)
• FDA Data Integrity and Laboratory Controls Guidance

Typical usage ratio

• Reference standards supplied at ≥99.9% purity, concentrations ranging from 1 mg to 100 mg per vial depending on analytical protocol

Downstream process integration

• Use as calibration material in HPLC, GC, and NMR quantification
• Reference for assay and impurity profiling in GMP quality control
• Proficiency sample material for QC laboratory accreditation

Final product types

• Certified reference vials for pharmaceutical testing
• Analytical control lots for release specification
• Comparator samples for regulatory batch release